On Friday, Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the consensus of $0.15.
The company reported sales of $730.52 million, up 18% year-over-year, beating the consensus of $707.6 million.
The increase was driven by Affordable Medicines (previously Generics) revenues growing 21% due to new product launches, biosimilars, and multiple other complex products, AvKARE revenues growing 14% due to new product launches, and Specialty revenues growing 16% driven by key branded products including CREXONT.
Also Read: Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock
It clocked a net loss of $31 million compared to a net loss of $99 million a year ago. Adjusted EBITDA in the fourth quarter of 2024 was $155 million, an increase of 9% compared to the fourth quarter of 2023, primarily due to strong revenue growth partially offset by higher spending in research and development and commercial initiatives to drive future growth.
Guidance: Amneal expects 2025 revenues of $3 billion—$3.1 billion and adjusted EPS of $0.65-$0.70 versus the consensus of $2.9 billion and $0.71, respectively.
"In 2025 and beyond, we are entering a new phase of growth by further expanding in high-growth areas such as Specialty, Biosimilars, and GLP-1 therapies. As a growing and diversified biopharmaceutical company, Amneal is well positioned to deliver substantial value creation for all our stakeholders," said Chirag and Chintu Patel, Co-Chief Executive Officers.
The company expects 2025 adjusted EBITDA of $650 million—$675 million, operating cash flow of $255 million—$285 million and capital expenditures of approximately $100 million.
Price Action: At the time of this writing, Friday, AMRX stock was up 1.43% at $8.50 during the premarket session.
Read Next:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.